Preliminary research suggests it may influence incretin hormone pathways, though clinical evidence supporting meaningful GLP-1 or GIP enhancement in humans is lacking
A meta-analysis of RCTs and cohort studies showed that SGLT2 inhibitors reduce the risk of AKI across diverse cardiovascular risk profiles [59,109], and are associated with lower mortality, major adverse kidney events, and MACE in acute kidney disease [110]
Jayne Hornung, chief clinical officer at Managed Markets Insight and Technology, suggests initial pricing of oral GLP-1s for weight loss could be reminiscent of the early days of anti-CGRP medications for migraines when the first oral CGRP came to market in 2019, the pricing still remained high
This, in turn, suppresses tumor growth and enhances chemotherapy efficacy
Treatment duration varies by individual
This comprehensive approach helps us ensure that we select the treatment most suited to each individuals health goals